HNP Capital’s AstraZeneca AZN Stock Holding History

HNP Capital’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-5,101	Closed	-$511K	–	136
2020 Q1	$511K	Buy	+5,101	New	+$480K	0.08%	141

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $53.8B AUM 19.23% 1-Year Est. Return

HNP Capital's AZN Position: Q2 2020 in Review

HNP Capital sold out of AstraZeneca (AZN) in Q2 2020, closing a stake of 5,101 shares — an estimated $511K sold.

HNP Capital first reported a position in AZN in Q1 2020 and held it in 1 quarter. The position peaked at $511K in Q1 2020. 669 funds tracked by Wall St. Rank hold AZN as of Q2 2020.

HNP Capital reported no remaining AstraZeneca position as of Q2 2020 after selling out during the quarter.
HNP Capital sold 5,101 AstraZeneca shares in Q2 2020, an estimated $511K.
HNP Capital first reported a position in AstraZeneca in Q1 2020 and held it in 1 quarter.
HNP Capital's AstraZeneca position peaked at $511K in Q1 2020.
669 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2020.

Based on HNP Capital's 13F filing for Q2 2020, filed 6 Jul 2020.